EUVIMEDEUVIMED entdecken
Crossref

Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma

David S Lee iD, Rajwant S Mahal, Theresa Tharakan iD, Cathryn Collopy, Dorina Kallogjeri, Wade L Thorstad, Douglas R Adkins, Peter Oppelt iD, Jessica Ley iD, Cameron C Wick iD, Jose Zevallos

Otolaryngology–Head and Neck Surgery · 2023

DOI: 10.1002/ohn.182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2023. Verfasst von David S Lee und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA. Hauptthemen laut MEDLINE: Carcinoma, Squamous Cell, Oropharyngeal Neoplasms, Papillomavirus Infections, Ototoxicity. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: NIDCD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To explore whether deintensification of adjuvant therapy reduces ototoxicity among patients with human papillomavirus (HPV)‐related oropharyngeal squamous cell carcinoma (OPSCC). Study Design Retrospective cohort study.

Setting

Single academic center.

Methods

The ototoxicity rate among adult patients with HPV‐related OPSCC enrolled in the Minimalist Trial (MINT), a prospective phase 2 trial of surgery followed by risk‐adjusted deintensified adjuvant therapy (42 Gy radiation given alone or with a single 100 mg/m 2 dose of cisplatin), was compared to that among a historical cohort treated with standard adjuvant therapy (60‐66 Gy radiation with up to three 100 mg/m 2 doses of cisplatin). Ototoxicity was defined as Common Terminology Criteria for Adverse Events v5.0 ≥ Grade 2. Mixed model analysis was performed to investigate the association between deintensified adjuvant therapy and treatment‐related hearing loss.

Results

A total of 29 patients (58 ears) were analyzed in the MINT cohort, and 27 patients (54 ears) in the historical cohort. The ototoxicity rate was 5% (n = 3/58 ears) in the MINT cohort and 46% (n = 25/54 ears) in the historical cohort (difference, 41%; 95% confidence interval [CI] = 27%‐56%). Patients in the MINT cohort demonstrated a 95% decrease in risk of ototoxicity compared to those in the historical cohort (adjusted odds ratio: 0.05, 95% CI = 0.01‐0.31). Differences in estimated marginal mean threshold shifts were statistically and clinically significant at frequencies ≥ 3 kHz.

Conclusion

The deintensified adjuvant therapy given in MINT led to less ototoxicity than standard adjuvant therapy among patients with HPV‐related OPSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Squamous CellOropharyngeal NeoplasmsPapillomavirus InfectionsOtotoxicityHead and Neck NeoplasmsAdultHumansSquamous Cell Carcinoma of Head and NeckHuman Papillomavirus VirusesCisplatinRetrospective StudiesProspective StudiesHearing

Stichwörter der Autor:innen

HPV-related oropharyngeal squamous cell carcinomacisplatin ototoxicityhearing outcomesp16+treatment deintensification

Substanzen

Cisplatin

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Division of Adult Audiology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Radiation Oncology, Washington University School of Medicine, St Louis, Missouri, USA.
  • Department of Medical Oncology, Washington University School of Medicine, St Louis, Missouri, USA.

ORCID-Profile: David S Lee, Theresa Tharakan, Peter Oppelt, Jessica Ley, Cameron C Wick

Förderung

  • NIDCD NIH HHS

Zitieren

APA

Lee, D. S., Mahal, R. S., Tharakan, T., Cathryn Collopy, Kallogjeri, D., Thorstad, W. L., Adkins, D. R., Oppelt, P., Ley, J., Wick, C. C., & Zevallos, J. (2023). Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.182

Vancouver

Lee DS, Mahal RS, Tharakan T, Cathryn Collopy, Kallogjeri D, Thorstad WL, et al. Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma. Otolaryngology–Head and Neck Surgery. 2023. doi:10.1002/ohn.182

BibTeX
@article{Lee2023,
  author = {Lee, David S and Mahal, Rajwant S and Tharakan, Theresa and Cathryn Collopy and Kallogjeri, Dorina and Thorstad, Wade L and Adkins, Douglas R and Oppelt, Peter and Ley, Jessica and Wick, Cameron C and Zevallos, Jose},
  title = {Hearing Outcomes in a Deintensification Trial of Adjuvant Therapy for HPV‐Related Oropharyngeal Squamous Cell Carcinoma},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2023},
  doi = {10.1002/ohn.182}
}
Kostenlos starten →